[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618444":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":38,"collaborators":42,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Advanced Lung Cancer Cohort",null,"Adults with suspected or confirmed stage IV lung cancer undergoing clinically indicated bronchoscopy with bronchoalveolar lavage. Participants are enrolled prospectively as a single observational cohort, and no treatment assignment or intervention is determined by the study. Bronchoalveolar lavage fluid is collected for immune profiling by flow cytometry, and study analyses stratify participants post hoc according to tumor PD-L1 expression levels and bronchoalveolar lavage T-cell immunophenotypes.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Deog Kyeom Kim, MD, PhD","CONTACT","+82-2-870-2228","kimdkmd@gmail.com",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Heemoon Park, MD","+82-2-870-3439","coramdeo33@gmail.com",[23],{"facility":24,"status":10,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"SMG-SNU Boramae Medical Center","Seoul","Dongjak-gu","07061","South Korea",{"type":30,"coordinates":31},"Point",[32,33],126.9784,37.566,{"lat":33,"lon":32},[36,37],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Deog Kyeom Kim","Professor, Department of Pulmonary and Critical Care Medicine, SMG-SNU Boramae Medical Center",[43],{"name":24,"class":6},"100618444",false,"NCT07331701","Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Patients with suspected or histologically confirmed stage IV lung cancer based on clinical and radiologic findings\n* Scheduled to undergo clinically indicated bronchoscopy with bronchoalveolar lavage as part of routine clinical care\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Receipt of treatment for acute lower respiratory tract infection (including pneumonia or fungal infection) within 4 weeks prior to bronchoscopy\n* History of solid organ transplantation or hematopoietic stem cell transplantation\n* Current use of systemic immunosuppressive therapy\n* Current or planned use of biologic immunomodulatory agents\n* Known autoimmune disease requiring systemic immunosuppressive treatment\n* Pregnant women\n* Patients with recurrent stage IV lung cancer after prior definitive therapy","ALL","19 Years",{"count":52,"type":53},60,"ESTIMATED","2 Years","OBSERVATIONAL","This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in predicting clinical outcomes in patients with advanced lung cancer. Although tumor PD-L1 expression measured on tissue biopsies is widely used to guide immunotherapy decisions, its predictive value is limited by spatial heterogeneity and sampling variability. By analyzing activated, exhausted, and regulatory T-cell populations in bronchoalveolar lavage fluid and examining their association with tissue-based tumor PD-L1 expression, this study seeks to determine whether combining local immune biomarkers with PD-L1 expression improves the prediction of treatment response and survival in patients receiving standard-of-care systemic therapy.",[58,59],"Lung Neoplasms","Tumor Immune Microenvironment",[61,62,63,64,65,59,66,67,68,69],"Bronchoalveolar Lavage Fluid","Tumor-Infiltrating T Lymphocytes","Programmed Cell Death 1 Ligand 1","Immune Checkpoint Inhibitors","Flow Cytometry","Treatment Response","Progression-Free Survival","Overall Survival","Predictive Biomarkers","NOT_YET_RECRUITING","2025-12-29",{"date":73,"type":74},"2026-01-12","ACTUAL",{"date":76,"type":53},"2026-01",{"date":78,"type":53},"2027-12-31",{"name":5,"class":6},1]